Summary Forty-five patients with restrictive respiratory diseases, including thoracic wall diseases (TWD, n ¼ 27) and neuromuscular diseases (NMD, n ¼ 18), underwent 18 months of home mechanical ventilation (HMV) treatment. Treatment consisted of a two-level pressure system for 7 h at night, with oxygen available if needed. Questionnaire-based assessments of health-related quality-of-life (HRQL) were evaluated before treatment and at 3, 6, 9, 12 and 18 months of follow-up. Hospitalization rates pre-and post-treatment were recorded, and the numbers need to treat (NNT) to avoid hospitalization and absolute risk reduction (ARR) rates were calculated. Several categories of HRQL, including physical function and vitality, improved significantly with treatment in both groups of patients; these improvements persisted over the entire 18 months. In contrast, other categories such as social function and mental health improved initially and declined subsequently. Hospitalizations decreased significantly with treatment. NNT calculations indicated that treatment would be needed for two TWD patients (ARR 63%) and one NMD patient (ARR 78%) to prevent one hospitalization per year per disease group. We conclude that improved quality-of-life and decreased hospitalizations make home non-invasive mechanical ventilation an useful treatment for patients with restrictive respiratory disorders.
Introduction
Home mechanical ventilation (HMV) has recently become a widely available procedure for the treatment of restrictive respiratory failure. In patients with thoracic wall diseases (TWD), HMV improves gas exchange, decreases dyspnoea and increases lung muscle endurance and maximum inspiratory pressure. However, some investigators have reported that HMV may not modify lung mechanics in those with neuromuscular diseases (NMD). [1] [2] [3] [4] HMV, as it is known, also improves healthrelated quality of life (HRQL) after 3 months of treatment and reduces the number of hospitalizations due to respiratory failure. [5] [6] [7] [8] Questionnaires to assess HRQL include instruments designed to solicit information on the overall repercussion of a particular therapy or regimen on the daily activity of the patients. However, the magnitude of the changes in HRQL in relation to the patients' clinical changes following treatment with HMV is not clearly known. The absolute risk reduction (ARR) of adverse effects of a treatment and its converse, the numbers needed to treat (NNT) to avoid these effects, are tools that provide a complete evaluation of the clinical significance and the magnitude of the changes achieved in the patient's HRQL. 9, 10 The objective of the present study was to investigate the long-term effect of HMV on HRQL and the rate of hospitalization. To evaluate the efficacy of HMV treatment we also calculated the ARR (i.e., aspects of the patient's HRQL that improve with HMV treatment) and the NNT (i.e., numbers of patients with restrictive pathology that would require treatment with HMV to avoid hospitalizations over a 1-year period).
Materials and methods

Patients
This was a prospective study of consecutive patients referred to the Pneumology Department of the University Hospital la Fe between January 1997 and November 2001 for evaluation for treatment with HMV. The patients had moderate to severe restrictive respiratory disorder resulting from TWD or various NMD, and they were clinically stable as defined by the absence of acute lung infection in the 3 months before the study. Informed consent was obtained from all patients. HMV was initiated if, according to the established consensus guidelines, the patients presented symptoms such as fatigue, dyspnoea, morning headache, and one of the following criteria: diurnal Pa-CO 2 445 mm Hg, forced vital capacity o50% of predicted in the NMD group and o40% of predicted in the TWD group, maximum inspired pressure o60 cm H 2 O, or oxygen saturation below 88% for more than five consecutive minutes as measured by nocturnal oximetry.
11,12
Methods
The patients who fulfilled the criteria for inclusion into the HMV program were hospitalized for 48-72 h to fit to ventilation pressure systems and to assess the HRQL before initiating therapy. HRQL was evaluated using the Spanish validated version of the SF36 questionnaire. 13 This instrument contains 36 items grouped into eight domains: Additionally, there was an independent category, the ''transition in health status'', that can be analysed as a quantitative variable providing information on the changes in health status that may have occurred between consecutive follow-up visits.
The patients indicated their current state by scoring each item from 0 to 100; lower scores reflected increasing impairment or severity of symptoms. For the ''health transition'' item, the value was obtained as the difference between the lower and the higher scores of successive follow-up visits. The reference values for the Spanish population, adjusted for age and sex, were obtained from Alonso et al. 14 Following the initial HRQL evaluation, the HMV was initiated using a bi-level pressure ventilation system (DP90 s ; Taema, Paris, France) with minimum inspiratory pressure of 10 cm H 2 O and expiratory pressure of 4 cm H 2 O. Commercial masks, such as the Sullivan s mask (Air Liquide Medicinal, Paris-France) or the Adams s mask (Air Liquide Medicinal, Paris-France), were used. Once the patients were fitted to the HMV system and PaCO 2 fell to a normal value or decreased at least 10 mm Hg, they were discharged from hospital. When the patients did not show the improvement in PaCO 2 , the pressures were gradually increased by 2 cm H 2 O of inspiratory and/or expiratory pressure per day until PaCO 2 decreased 10 mm Hg or returned to a normal level. At this point, the patients were discharged from hospital and instructed to continue with the procedure for 7 h every night. An oxygen supplement was made available for those patients whose PaO 2 was o55 mm Hg.
The follow-up visits at 3, 6, 9, 12 and 18 months were conducted in the outpatient clinic. HRQL was evaluated at each visit. Adherence to treatment was assessed through a weekly reading of the timer-counter in the ventilator. The mechanical functioning of the machine and the state of the masks were checked regularly. The patients had access to 24 h emergency telephone consultation. A register of the number of hospitalizations for acute respiratory failure before and after the treatment with HMV was maintained throughout the study.
Statistical analyses
All statistical analyses were performed using SPSS version 10.0 for Windows 98. Comparisons between groups of patients were performed with the Student's t-test. The pre-and post-HMV data of the HRQL were analysed using ANOVA with the Bonferroni correction. In those categories in which statistically significant differences were encountered, the ARR (the greater value meant the better result), its reciprocal (1/ARR) and the NNT (the lower value meant the better result) were calculated. The number of hospitalizations pre-and post-HMV was compared using the Student's unpaired t-test. All values of Po0:05 were considered statistically significant.
Results
From the 67 patients (36 with TWD and 31 with NMD) who started the study, 45 (27 with TWD and 18 with NMD) completed the 18 months of treatment. Twelve of the 22 remaining patients (9 with amyotrophic lateral sclerosis and 3 with kyphoscoliosis) died during follow-up because of acute respiratory failure (n ¼ 8) or community acquired pneumonia (n ¼ 4); 10 patients (6 with TWD and 4 with NMD) abandoned the treatment because of failure to fit to the ventilation system.
The mean age of the 27 patients (16 men, 11 women) with TWD was 55.6 years. Diagnosis were: kyphoscoliosis (n ¼ 22), fibrothorax (n ¼ 3) and thoracoplasty (n ¼ 2). The mean age of the 18 patients (9 men, 9 women) with NMD was 42.5 years. Neuromuscular patients were: spinal atrophy
As recorded on the machine's timer-counter, the patients used the HMV system for a mean of 6 h per night. Oxygen supplementation was required during the night in 19 cases (11 with TWD and 8 with NMD) and was withdrawn later for most patients when oxygen saturation had improved. Twenty patients, mainly from the TWD group, used telephone consultations. Table 1 shows the baseline PaO 2 , PaCO 2 , SaO 2 and FVC in both groups. Table 2 summarizes the baseline values of the HRQL domains in the two groups of patients. The data indicate that, in both types of pathology, most of the categories were located between the 5th and 25th percentiles of the reference population. The physical function category in both groups of patients and the social function domain in the males with TWD were lower than the 5th percentile. Body pain and social function categories in the women with TWD, and body pain and mental health in the women with NMD, were located between the 25th and 50th percentiles. There were no significant differences in either group in the domains of HRQL as a function of gender. Figures 1 and 2 show the changes in HRQL categories at 3, 6, 9, 12 and 18 months of treatment with HMV in the patients with TWD and NMD, respectively. The patients with TWD presented significantly higher scores in physical function, physical capacity, vitality, emotional capacity and health transition at 3 months of treatment; these differences maintained over the 18 months of treatment. Similarly, social function and mental capacity improved significantly at the 6th month of treatment, and began to diminish subsequently from about 1 year of treatment, although these did Tables 3 and 4 show the ARR and NNT for patients with TWD and NMD, respectively. The ARR and NNT were calculated in those domains of the HRQL questionnaire that improved significantly during the follow-up.
ARTICLE IN PRESS
The number of hospitalizations decreased significantly following HMV treatment in both groups of patients. In the patients with TWD, the mean annual rate of hospitalizations decreased from 1.52 hospitalizations per year before ventilation therapy to 0.89 after it (P ¼ 0:002). The calculated ARR in this group was 63% (range 26-100%) with two patients needing treatment (range 1-4) to preclude one hospitalization per year. The mean hospitalization rate in the patients with NMD was 1.22 per year before ventilation and 0.44 per year after HMV therapy (P ¼ 0:001). The calculated ARR was 78% (range 38-100%), and the NNT indicated one patient needing treatment (range 1-3) to avoid one hospitalization per year.
Discussion
The impact of HMV on the HRQL in patients with restrictive respiratory diseases has been previously evaluated, [5] [6] [7] although the natural history of the changes over time has not been fully studied. Our results allow us to propose that HMV can have a positive impact, with considerable clinical consequences, on the patients undergoing this treatment. In the present series of patients, HMV improved the HRQL of patients with TWD even over the short study period, and these changes were maintained over a longer period. It appears to be necessary to treat only a small number of patients to elicit an improvement in various categories of HRQL. The improvement in the HRQL in the patients with NMD was not so readily apparent. The rate of improvement in some HRQL domains slowed over time, which corresponded to disease progression, although the scores did not achieve the pre-treatment level. However, the ARR and NNT results indicate that the number of patients requiring HMV to avoid one hospitalization per year was lower in the NMD than in the TWD group. The pre-existing differences in HRQL between the two groups before the therapy, together with the heterogeneity and natural history of NMD (especially of ALS), can explain the different degrees of response to treatment observed between the patients with TWD and NMD. The benefits of the HMV treatment in patients with 16 appeared to be satisfied with HMV.
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In a previous study in patients with the same characteristics, we attributed the initial improvement in HRQL in the group with TWD and its persistence over a protracted period to the improvement in gas exchange and to the lower grade of dyspnoea following the HMV treatment. 8 Similarly, the better HRQL observed in patients with NMD appeared to be related to the better blood gases level found in these patients following HMV. We proposed that the subsequent deterioration could be due to the decreases in FVC and FEV 1 observed in the long-term follow-up on these patients. 8 From the results of the present study, we are able to identify an additional variable that can explain the improvement in HRQL; i.e., the lower number of hospitalizations that result in both groups of patients following the implementation of HMV. However, we need to highlight the paradoxical finding that the decrease in the number of hospitalizations for acute respiratory failure in the patients with NMD was noticeable, although their HRQL was worse than that of patients with TWD. Conversely, the TWD patient group had a much better HRQL than the patients with NMD, but required more hospitalizations, albeit fewer than before implementation of the HMV treatment. At present, it seems difficult to explain this finding.
Additional factors may have contributed to the improved HRQL and hospitalization rates achieved with the HMV treatment, such as the regular follow-up and telephone consultation available to all the patients undergoing the treatment. However, we must remark that outpatient appointments were similar pre-and post-HMV and records of the telephone calls indicated that most were related to technical aspects of the equipment.
The lack of a control group and the relatively small number of patients included in the present trial constitute the principal limitations of the study. However, ethical constraints preclude us withholding the clearly efficacious treatment from these types of patients merely to have controlgroup data available. In addition, the frequent and protracted follow-up could compensate for the relatively small numbers of patients studied.
In conclusion, we believe that HMV is a procedure that improves HRQL in patients with restrictive respiratory diseases, especially those suffering from TWD and this finding is long lasting. In contrast, HRQL does not show such improvement in NMD patients and this amelioration is shorter. However, patients with NMD had a reduced number of hospitalizations together with a better ARR and NNT than did patients suffering from TWD. Given that these changes are highly relevant for these patients, we consider that the HMV is a suitable therapy for most patients suffering from restrictive respiratory diseases.
